[go: up one dir, main page]

DK3351255T3 - Modificerede anti-cd4-antistoffer - Google Patents

Modificerede anti-cd4-antistoffer Download PDF

Info

Publication number
DK3351255T3
DK3351255T3 DK18159086.0T DK18159086T DK3351255T3 DK 3351255 T3 DK3351255 T3 DK 3351255T3 DK 18159086 T DK18159086 T DK 18159086T DK 3351255 T3 DK3351255 T3 DK 3351255T3
Authority
DK
Denmark
Prior art keywords
antibodies
modified anti
modified
Prior art date
Application number
DK18159086.0T
Other languages
English (en)
Inventor
Stephan Fricke
Frank Emmrich
Nadja Hilger
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Application granted granted Critical
Publication of DK3351255T3 publication Critical patent/DK3351255T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18159086.0T 2010-12-02 2011-12-02 Modificerede anti-cd4-antistoffer DK3351255T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10015236A EP2471543A1 (en) 2010-12-02 2010-12-02 Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
EP11801972.8A EP2672979B1 (en) 2010-12-02 2011-12-02 Anti cd4 antibodies to prevent in particular graft-versus-host-disease (gvhd)

Publications (1)

Publication Number Publication Date
DK3351255T3 true DK3351255T3 (da) 2020-10-19

Family

ID=43903838

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18159086.0T DK3351255T3 (da) 2010-12-02 2011-12-02 Modificerede anti-cd4-antistoffer
DK11801972.8T DK2672979T3 (da) 2010-12-02 2011-12-02 Anti-cd4-antistoffer til forebyggelse af især graft-versus-host-sygdom (gvhd)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11801972.8T DK2672979T3 (da) 2010-12-02 2011-12-02 Anti-cd4-antistoffer til forebyggelse af især graft-versus-host-sygdom (gvhd)

Country Status (10)

Country Link
US (3) US9745552B2 (da)
EP (3) EP2471543A1 (da)
JP (2) JP6008863B2 (da)
KR (2) KR101870277B1 (da)
CA (1) CA2819520C (da)
DK (2) DK3351255T3 (da)
ES (2) ES2824767T3 (da)
HU (2) HUE040300T2 (da)
PL (1) PL2672979T3 (da)
WO (1) WO2012072268A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
WO2014090985A1 (en) * 2012-12-13 2014-06-19 Universität Leipzig T-cell modulation by exon skipping
WO2016073845A1 (en) * 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
ES3020458T3 (en) 2015-08-07 2025-05-22 Imaginab Inc Antigen binding constructs to target molecules
ES2992025T3 (es) * 2016-02-15 2024-12-05 Fraunhofer Ges Zur Foerderungder Angewandten Forschung E V Prevención del rechazo de injerto mediante el uso previo de injertos modificados
AU2019282248A1 (en) 2018-06-08 2021-01-07 Imaginab, Inc. Antigen binding constructs to CD4
EP3957364A1 (en) * 2020-08-20 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN116693687B (zh) * 2023-08-03 2023-10-03 天津旷博同生生物技术有限公司 一种抗人cd25工程抗体及应用
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108664T1 (de) * 1987-12-02 1994-08-15 Becton Dickinson Co Verfahren zur verhütung von gvhd.
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
DE3919294C2 (de) 1989-06-13 1998-04-23 Frank Prof Dr Emmrich Verwendung eines monoklonalen Antikörpers zur Behandlung einer Autoimmunerkrankung
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
JP2822586B2 (ja) 1990-04-19 1998-11-11 富士ゼロックス株式会社 インクジェットプリンター
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
PT840618E (pt) * 1995-05-18 2003-08-29 Ortho Mcneil Pharm Inc Inducao de tolerancia imunologica atraves de anticorpos anti-cd4 nao-depletores
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
DK1616579T3 (da) * 1998-05-23 2009-09-14 Univ Leiden Medical Ct CD40 bindende molekyler og CTL peptider til behandling af tumorer
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
WO2001068813A1 (en) * 2000-03-10 2001-09-20 Thomas Jefferson University L-leucyl-l-leucine methyl ester treatment of donor lypmhocyte infusions in hematopoietic stem cell transplant patients
CA2469901C (en) 2001-12-11 2017-07-04 Biotectid Gmbh Use of a labelled ligand having specificity for the human cd4 molecule to produce a diagnostic agent for analysing migration and/or distribution patterns of cell populations
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
BRPI0512017A (pt) * 2004-06-22 2008-02-06 Tolerrx Inc dosagem otimizada com anticorpos anti-cd4 para indução de toleráncia em primatas
WO2006017173A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
ES2593789T3 (es) * 2007-02-01 2016-12-13 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
CN102271711B (zh) * 2008-12-12 2014-06-18 国立大学法人东京大学 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
ES2992025T3 (es) * 2016-02-15 2024-12-05 Fraunhofer Ges Zur Foerderungder Angewandten Forschung E V Prevención del rechazo de injerto mediante el uso previo de injertos modificados

Also Published As

Publication number Publication date
PL2672979T3 (pl) 2019-03-29
US10577588B2 (en) 2020-03-03
CA2819520A1 (en) 2012-06-07
US20130330334A1 (en) 2013-12-12
US20180051254A1 (en) 2018-02-22
ES2824767T3 (es) 2021-05-13
KR101870277B1 (ko) 2018-06-26
WO2012072268A3 (en) 2012-09-13
JP2017039732A (ja) 2017-02-23
HUE040300T2 (hu) 2019-02-28
EP3351255A1 (en) 2018-07-25
EP3351255B1 (en) 2020-08-26
DK2672979T3 (da) 2019-01-02
WO2012072268A2 (en) 2012-06-07
EP2672979A2 (en) 2013-12-18
EP2672979B1 (en) 2018-09-19
US20180030414A1 (en) 2018-02-01
JP6008863B2 (ja) 2016-10-19
KR101739620B1 (ko) 2017-05-24
HUE051199T2 (hu) 2021-03-01
JP2014501731A (ja) 2014-01-23
JP6276818B2 (ja) 2018-02-07
US9745552B2 (en) 2017-08-29
WO2012072268A8 (en) 2013-03-28
KR20140027075A (ko) 2014-03-06
ES2701760T3 (es) 2019-02-25
KR20160052809A (ko) 2016-05-12
US10227564B2 (en) 2019-03-12
CA2819520C (en) 2021-06-22
EP2471543A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
LTPA2019011I1 (lt) CGRP antikūnai
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
HUE056313T2 (hu) Anti-DLL3 antitest
BR112012030311A2 (pt) anticorpo
DK2521736T3 (da) Humaniserede antistoffer
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL222272B (en) Anti-erbb3 antibodies
DK3284754T3 (da) Anti-cd38-antistoffer
EP2566517A4 (en) BINDER ANTIBODY CSF1R
CO6791565A2 (es) Anticuerpos anti-notch1
DK3741883T5 (da) Antistofbiblioteker
PT2406284T (pt) Anticorpos anti-bcma
CO6811812A2 (es) Anticuerpo anti-b7-h3
IL231777A0 (en) Antibodies against tl1a and uses thereof
HUE036229T2 (hu) CEA antitestek
DK3178851T3 (da) Anti-cd40-antistoffer
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
HRP20181320T8 (hr) Ljudska anti-tau protutijela
CR20140127A (es) Anticuerpo anti-abtcr
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
SMT201700083B (it) Anticorpi monoclonali
DK3202789T3 (da) Anti-vla-4-antistoffer
HUE036157T2 (hu) Humanizált IL-25 ellenanyagok
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną